

Ipilimumab MDX010-20

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



Ipilimumab MDX010-20

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era)  
Experimental Arm: Ipilimumab  
Control Arm: Glycoprotein 100 (GP100)



